Another therapeutic strategy in ARMS involves targeting heme oxygenase-1 (HO-1), an enzyme upregulated in ARMS that promotes proliferation and angiogenesis while suppressing muscle differentiation. Here, HMOX1 is linked to alveolar rhabdomyosarcoma.